<DOC>
	<DOC>NCT01966497</DOC>
	<brief_summary>The main objective of this observational survey is to estimate the incidence, the typology, and the evolution of patients with acute myelobalstic leukemia, aged more than 60 years old. In this age group (aged more than 60y), three groups of patients with very different response rates and late outcome can be delineated with specific standard chemotherapy.</brief_summary>
	<brief_title>Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Aged 60 years or more With a morphologically proven diagnosis of AML according to WHO 2008 classification Not previously treated for AML Signed informed consent. APL in the WHO classification. Ph1positive AML or prior Ph1positive disease AML evolving from a prior MPN in the WHO 2008 classification. Prior tumor, if not stable for at least two years, except insitu carcinoma and skin carcinoma ECOG Performance Status Score &gt; 3 Positive serology for HIV or HTLV1, or active viralinfection for HBV and HBC. Severe uncontrolled infection at inclusion time. Psychiatric disease or an history of noncomplianceto medical regimens or patients considered potentially unreliable. Absence of Health Care Insurance</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>AML</keyword>
</DOC>